GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.
Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...
GSK announced on Wednesday that it has reached confidential settlements in two lawsuits filed in California State Court ...
GlobalData on MSN4d
MHLW accepts GSK’s multiple myeloma treatment NDA for reviewJapan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback